New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novo Nordisk A/S

NVO

Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.

Revenue
+3.87%
EPS
−17.1%
Free cash flow
−14.8%
Total debt
+30.7%

Quarter to September 2026, against a year earlier

38.56 0.33 −0.85%
Market cap
$128.6B
P/E
9.8×
Fwd P/E FY26e
—
Dividend yield
4.62%
F-score
5/9
ROIC
29.6%
Net debt / EBITDA
0.7×
Payout ratio
0.5×

Novo Nordisk A/S (NVO) news

The news and the share price important stories, numbered as below

Share price since Oct 21 −1.3%

Stories the last two months, newest first

  1. Commentary ·

    Novo’s dividend yield is about 4.6%

    Novo Nordisk’s dividend yield is about 4.6%, with dividends rising from $0.62 per share in 2019 to $1.85 in 2026. Its payout ratio is around 45%, and buybacks bring shareholder yield to roughly 5.5%. Shares trade at a price-to-sales ratio below their five-year average, while competition and clinical setbacks remain risks.

    Reported by The Motley Fool

  2. Deal ·

    Novo and nference partner on cardiometabolic disease research

    Novo Nordisk and nference will combine Novo’s clinical-trial research with nference’s AI platform and federated real-world healthcare data to study cardiometabolic disease, treatment outcomes, safety, and long-term health. The collaboration will explore clinical pharmacology, combination therapies, and precision trials, with an additional framework for creating AI- and data-focused ventures in cardiometabolic health and healthy ageing.

    Reported by PR Newswire

  3. Commentary ·

    Simply Wall St sees possible upside in Novo shares

    Novo Nordisk shares have fallen 57.9% in three years and trade near US$40.70. Their 10.7x P/E is below the pharmaceutical industry’s 17.1x average and a tailored fair P/E benchmark, suggesting the shares may be undervalued on current earnings. A community investor narrative estimates 57% upside, while analyst forecasts offer another valuation perspective.

    Reported by Simply Wall St

  4. Commentary ·

    Simply Wall St values Novo shares above their recent price

    Novo Nordisk’s Anthropic collaboration is drawing attention as investors assess whether AI can improve drug discovery and software development. A Simply Wall St community valuation estimates fair value at $76.63 per share, 46.9% above the recent $40.70 price. The bullish case faces risks from persistent US pricing pressure and possible disappointment from CagriSema or other therapies.

    Reported by Simply Wall St

  5. Product ·

    Novo relaunches NovoCare support program for Wegovy users

    Novo Nordisk is relaunching its free NovoCare membership with Wegovy treatment and coverage information, home delivery, coaching, progress tracking, wellness partners and planned rewards. Expanded delivery will soon be available to eligible members with commercial or government insurance, including Medicare Bridge; NovoCare Points are planned by year-end.

    Reported by PR Newswire

  6. 4 Product ·

    Novo receives EU approval for FREHEMGO in haemophilia A

    The European Commission approved Novo Nordisk’s FREHEMGO (denecimig) for routine prevention of bleeding in adults and children with haemophilia A, with or without inhibitors. The subcutaneous treatment offers monthly, every-two-week or weekly dosing via a pre-filled pen. Novo plans to launch in the first European countries within the year; the treatment is also approved in Saudi Arabia and under review by the US FDA and other regulators.

    Reported by 2: Simply Wall St · GlobeNewswire

  7. 5 Product ·

    Novo reports about 21% weight loss with lower-dose CagriSema

    In the 68-week phase 3 REDEFINE 9 trial, investigational CagriSema at 1.7 mg/1.7 mg and 1.0 mg/1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, versus 2.0% with placebo if participants stayed on treatment. Both doses had significantly better weight-loss and waist-circumference outcomes than placebo; CagriSema remains investigational.

    Reported by 2: PR Newswire · Zacks

  8. Product ·

    Novo reports 25.4% weight loss among early CagriSema responders

    Novo Nordisk said post-hoc analyses of a late-stage trial found 67.8% of adults taking CagriSema lost at least 5% of their weight within eight weeks; these early responders averaged 25.4% weight loss at week 68, compared with 17.8% among slower responders. Digestive side effects were more common with CagriSema, and 5.9% stopped treatment because of side effects, versus 3.5% on placebo.

    Reported by 3: GuruFocus · InvestorsHub · GuruFocus

  9. Product ·

    Novo reports phase 3 Wegovy results in children aged 6 to under 12

    At week 68, BMI fell 17.4% in the semaglutide group versus a 2.2% increase with placebo; nearly 79% achieved at least a 10% BMI reduction. Safety was consistent with previous trials, with no identified concerns for growth or puberty. Semaglutide is investigational for children under 12 in the United States and is not approved for this age group.

    Reported by PR Newswire

  10. Product ·

    Novo reports lower food-noise scores in Wegovy real-world studies

    In the injection study, food-noise scores declined within the first month and remained lower through six months. In the oral semaglutide study, average scores fell about 25% over three months, and 86.4% of participants reported at least one treatment improvement. The retrospective analyses used patient-reported data from Ro’s telehealth platform and cannot establish causality.

    Reported by PR Newswire

  11. 3 Product ·

    Novo submits etavopivat for US and European approval

    The applications are based on the Phase 3 HIBISCUS trial, in which etavopivat reduced vaso-occlusive crises by 27% and delayed the first crisis by about four months versus placebo. Regulators are expected to act in 2027. Etavopivat is an investigational once-daily treatment for people aged 12 and older with sickle cell disease.

    Reported by 3: PR Newswire · Stocktwits · InvestorsHub

  12. Product ·

    Novo partners with DJ Khaled to promote Wegovy

    Novo Nordisk partnered with DJ Khaled to promote Wegovy and share his weight-management experience, including his reported 75-pound loss after a year on the drug alongside diet and exercise. The campaign encourages people considering treatment to speak with a healthcare professional.

    Reported by 2: PR Newswire · Simply Wall St.

  13. 2 Product ·

    Novo’s Wegovy pill surpasses eight million US prescriptions

    The Wegovy pill launched in the U.S. in January 2026 and generated DKK 5.4 billion in third-quarter sales, with U.S. prescriptions topping eight million since launch. Strong oral demand helped drive 22% growth in the obesity franchise and supported an improved 2026 outlook, though injectable Wegovy, Ozempic and Rybelsus sales declined. Novo faces growing competition from Eli Lilly’s GLP-1 drugs and oral obesity pill.

    Reported by 3: The Motley Fool · Zacks · The Motley Fool

  14. Commentary ·

    Simply Wall St says Novo shares trade below its fair-value estimate

    Novo Nordisk shares have fallen 55.9% over three years to DKK 272.70, despite continued interest in its GLP-1 obesity and diabetes treatments. The stock trades at 10.6 times earnings, below the pharmaceutical industry average, peer group, and Simply Wall St's Fair Ratio model, suggesting it may be undervalued. Investor views differ over competition, pricing, future launches, and growth expectations.

    Reported by Simply Wall St.

  15. Legal ·

    FDA asks GLP-1 makers to add rare vision-loss warnings

    The FDA is asking GLP-1 manufacturers, including Novo Nordisk, to add warnings about rare sudden vision loss from NAION after reviewing trial and real-world reports. The label change raises safety, legal and market-access risks for Wegovy, but does not alter Novo Nordisk’s growth plans for obesity treatment and broader cardiometabolic indications.

    Reported by Simply Wall St.

  16. Product ·

    Novo reports liver-marker findings in a Wegovy MASH subgroup

    Novo Nordisk reported a post hoc analysis of 106 ESSENCE trial participants with MASH, liver scarring, and BMI below 27 kg/m². At week 72, semaglutide 2.4 mg was associated with better liver enzyme, disease activity, and several fibrosis-marker results versus placebo; the VCTE-LSM result was not statistically conclusive. The exploratory findings require further validation.

    Reported by 2: PR Newswire · GuruFocus.com

  17. Commentary ·

    Zacks rates Novo shares Hold after quarterly results

    Novo Nordisk shares rose 4.3% in a month after stronger-than-expected third-quarter results, improved 2026 guidance and strong Wegovy pill uptake. Its obesity franchise, expanding semaglutide indications and pipeline offer growth opportunities, while competition from Eli Lilly, pricing pressure, weaker diabetes sales and CagriSema’s trial setback cloud the outlook. Zacks rates NVO Hold.

    Reported by Zacks

  18. 1 Results ·

    Novo raises 2026 outlook after third-quarter sales rise

    Third-quarter adjusted sales rose 4% to DKK 79.2 billion, while operating profit rose 27% to DKK 32 billion, partly due to lower transformation costs. Novo raised its 2026 adjusted sales and operating profit growth outlook to -2% to 2% at constant exchange rates and lifted its free cash flow forecast to DKK 60 billion–70 billion.

    Reported by 2: The Motley Fool · MarketBeat

  19. Product ·

    Novo reports real-world Wegovy findings in adults with MASH

    In PLATINUM-Truveta, adults with MASH using semaglutide 2.4 mg had greater six-month weight loss and reductions in AST and HbA1c than resmetirom users; ALT differences were not statistically significant. In RHODIUM-2, semaglutide initiators had greater 12-month reductions in liver enzymes, weight and HbA1c than non-initiators. Both observational studies have limitations and cannot establish causation.

    Reported by 2: PR Newswire · Simply Wall St.

  20. Leadership ·

    Novo names Galderma CFO Luigi La Corte as successor to Karsten Munk Knudsen

    Novo Nordisk CFO Karsten Munk Knudsen will leave at year-end after 27 years with the company, and Luigi La Corte, currently CFO at Galderma, will succeed him. Knudsen’s tenure included the Wegovy launch, nearly tripled operating profit and cash flow, and expanded manufacturing capacity. Novo has not disclosed La Corte’s compensation.

    Reported by cfodive.com

  21. Other ·

    Novo plans obesity data presentations at ObesityWeek 2026

    Novo Nordisk plans to present real-world Wegovy findings across age groups and telehealth settings, alongside investigational CagriSema weight-loss and REDEFINE data, at ObesityWeek 2026 in early November. The results could inform views on the company’s obesity portfolio amid manufacturing expansion, competition, and pricing pressure, but do not resolve those uncertainties.

    Reported by Simply Wall St.

More headlines